Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
Date:8/24/2011

AMSTERDAM, The Netherlands, August 25, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

Highlights

  • Glybera®:
    • Data showing Glybera produces significant reduction in risk of pancreatitis in LPLD patients presented at European Atherosclerosis Society Meeting
    • CHMP does not consider Glybera approvable at this time
    • Chylomicrons now validated as biomarker for Glybera efficacy; data presented at American Society of Gene and Cell Therapy annual meeting
    • AMT generating further chylomicron data from existing treated patients to support re-examination process
    • Submitted for re-examination, outcome expected before end 2011
  • Collaboration with Institut Pasteur-led Consortium to develop Sanfilippo B gene therapy product for cGMP manufactured material; worth up to € 1.8 million to AMT
  • € 1.1 million funding for Acute Intermittent Porphyria gene therapy product as part of EU Consortium
  • Grant from Dutch Parents Association for Duchenne Muscular Dystrophy gene therapy
  • Appointment of Dr. Carlos R. Camozzi as Chief Medical Officer
  • Key financial figures in line with guidance
  • Cash & cash equivalents of € 9.1 million at June 30, 2011, in line with budget

"We have moved quickly and have already filed an application for re-examination of Glybera, after the initial disappointment with the CHMP opinion in June. We are continuing to collect more data to show that there is a long-term reduction in the incidence of pancreatitis in treated patients.  We will be able to generate the additional data required from the existing treated patients, and the data will come from a trial which we had already pla
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Molecular sleuths track evolution through the ribosome
11. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... intensively investigated for application as catalysts, sensors, ... components in photonics and molecular electronics. Gaining ... understanding physical and chemical properties, has been ... have demonstrated that high-resolution electron microscopy can ... in which all gold atoms are observed. ...
(Date:8/22/2014)... 22, 2014 The AMA is pleased ... members in Alaska that Alaska Governor Sean Parnell has ... further defining public use of Unmanned Aircraft Systems and ... House Bill 255states that it is, “An Act relating ... by an unmanned aircraft system.” It defines State of ...
(Date:8/21/2014)... Rockville, MD (PRWEB) August 21, 2014 ... is making progress in its development of JRC-LAMP-vax, an ... red cedar pollen. Phase IC studies began this month ... solution to hay fever. , The Japanese red cedar ... million people in Japan. Mountain Cedar pollen wreaks similar ...
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the ... of His Majesty Willem-Alexander, King of the Netherlands, has ... of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant ... King will take part in the Grand Opening Ceremony ... a.m.-12:20 p.m. and tour the plant. POET-DSM is a ...
Breaking Biology Technology:A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy 2State of Alaska Signs Unmanned Aircraft Systems Bill 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3
... , , STOCKHOLM , January ... the formation of BioChromix Pharma AB, a,new company working to develop ... Development will initially take,28 percent ownership in the new company. , ... as they have a novel,approach that targets the cause of the ...
... , FORT WORTH, Texas , ... Board: WNDM), announced today that it is nearing the completion of its ... first distributor in that country.  Numerous physicians in the nation have ... with its speed and efficacy in the management of diabetic ulcers ...
... , WILMINGTON, Del. , and ... DD ) and BASF Plant Science announced they have reached an ... DuPont and BASF filed suit against each other in U.S. Federal Court ... property rights relating to biotechnology traits, including traits that provide tolerance to ...
Cached Biology Technology:Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 2Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 3Wound Management Technologies, Inc. Rapidly Expands Its International Presence 2Wound Management Technologies, Inc. Rapidly Expands Its International Presence 3Wound Management Technologies, Inc. Rapidly Expands Its International Presence 4DuPont and BASF Announce Settlement 2DuPont and BASF Announce Settlement 3
(Date:8/21/2014)... the water window? It consists of radiations in the ... by the water in biological tissues. New theoretical findings ... within the water window. These could be the basis ... of the biological samples or to be used in ... physical mechanism needed to efficiently generate the harmonic radiationswhich ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
(Date:8/20/2014)... Aug. 20, 2014 George E. Fox, a John and ... of Houston (UH), was named a fellow in the International ... , Fox is one of four members two ... chosen as fellows in 2014. Fellows are elected every ... more than 500 members from more than 20 countries, the ...
Breaking Biology News(10 mins):Water window imaging opportunity 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3UH professor named fellow by International Astrobiology Society 2
... emphasizes the development of a series of nested environment ... with the individual, and also affect the development of ... is the major source influencing human development, which is ... saw the individual,s experience "as a set of nested ...
... N. Kuggie Vallee Foundation announces, today, the first recipients ... are: Dr. Kirsty L. Spalding, Senior Researcher in ... Karolinska Institutet (Stockholm, Sweden) who studies obesity by investigating ... David Tobin, Assistant Professor of Molecular Genetics and Microbiology ...
... enhance mental energy and well-being not only for healthy ... according to a July 15 panel discussion at the ... Food Expo held at McCormick Place. Bonnie Kaplan, ... University of Calgary, Alberta, Canada, said Monday vitamins and ...
Cached Biology News:
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
Immunogen: Tissue / cell preparation. (Murine EHS laminin preparation) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
Mouse monoclonal [Flt-1/EWC] to VEGF Receptor 1 ( Abpromise for all tested applications). entrezGeneID: 2321 SwissProtID: P17948...
Biology Products: